Specialistpharmaceutical company Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) is pleased toannounce that the U.S. Aridol Phase III clinical trial in subjects withsuspected asthma has finished recruitment. The trial was conducted in over400 subjects in 30 hospitals throughout the U.S. The trial compared Aridol with acknowledged methods for diagnosingairway responsiveness in subjects suspected of having asthma. Its designwas based on discussions with the U.S. [click link for full article]
(more...)